Adjunctive antibiotic therapy with rifaximin may help reduce crohn's disease activity

Digestive Diseases and Sciences

Volumn 55, Issue 4, 2010, Pages 1079-1084

  Shafran, Ira ^a   Burgunder, Patricia ^a  

^a Shafran Gastroenterology Center   (United States)

Author keywords

Crohn's disease; Crohn's disease activity index; Inflammatory bowel disease; Nonsystemic antibiotic; Rifaximin

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; IMMUNOMODULATING AGENT; INFLIXIMAB; RIFAXIMIN; STEROID; ANTIINFECTIVE AGENT; CORTICOSTEROID; RIFAMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED; RECURRENT DISEASE;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RIFAMYCINS; YOUNG ADULT;

EID: 77950344360     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1111-y     Document Type: Article

References (29)

1. JL Cameron SR Hamilton J Coleman JV Sitzmann TM Bayless 1992 Patterns of ileal recurrence in Crohn's disease. A prospective randomized study Ann Surg 215 546 551 10.1097/00000658-199205000-00018 1:STN:280:DyaK38zhtlWnsA%3D%3D 1616391 (discussion 551-542)
2. DK Podolsky 2002 Inflammatory bowel disease N Engl J Med 347 417 429 10.1056/NEJMra020831 1:CAS:528:DC%2BD38XlvFKrt7s%3D 12167685 (Pubitemid 34851835)
3. P Rutgeerts K Goboes M Peeters M Hiele F Penninckx R Aerts R Kerremans G Vantrappen 1991 Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum Lancet 338 771 774 10.1016/0140-6736(91)90663-A 1:STN:280:DyaK38%2Fhs1Olsw%3D%3D 1681159
4. RB Sartor 2006 Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis Nat Clin Pract Gastroenterol Hepatol 3 390 407 10.1038/ncpgasthep0528 1:CAS:528:DC%2BD28XnslKjs7o%3D 16819502 (Pubitemid 44018812)
5. DJ Marks AW Segal 2008 Innate immunity in inflammatory bowel disease: a disease hypothesis J Pathol 214 260 266 10.1002/path.2291 1:CAS:528: DC%2BD1cXhvFCkt7c%3D 18161747 (Pubitemid 351160162)
6. WS Mow EA Vasiliauskas YC Lin PR Fleshner KA Papadakis KD Taylor CJ Landers MT Abreu-Martin JI Rotter H Yang SR Targan 2004 Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease Gastroenterology 126 414 424 10.1053/j.gastro.2003.11.015 1:CAS:528: DC%2BD2cXhvV2rsbg%3D 14762777 (Pubitemid 38182298)
7. NS Ambrose RN Allan MR Keighley DW Burdon D Youngs P Barnes JE Lennard-Jones 1985 Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study Dis Colon Rectum 28 81 85 10.1007/BF02552649 1:STN:280:DyaL2M7is1ehug%3D%3D 3882364 (Pubitemid 15131968)
8. GL Arnold MR Beaves VO Pryjdun WJ Mook 2002 Preliminary study of ciprofloxacin in active Crohn's disease Inflamm Bowel Dis 8 10 15 10.1097/00054725-200201000-00002 11837933
9. P Blichfeldt JP Blomhoff E Myhre E Gjone 1978 Metronidazole in Crohn's disease. A double blind cross-over clinical trial Scand J Gastroenterol 13 123 127 10.3109/00365527809179816 1:STN:280:DyaE1c7jvVeqtA%3D%3D 345410
10. J-F Colombel M Lemann M Cassagnou Y Bouhnik B Duclos J-L Dupas B Notteghem JY Mary 1999 A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease Am J Gastroenterol 94 674 678 10.1111/j.1572-0241.1999.935-q.x 1:CAS:528:DyaK1MXitV2ku7s%3D 10086650
11. K Leiper AI Morris JM Rhodes 2000 Open label trial of oral clarithromycin in active Crohn's disease Aliment Pharmacol Ther 14 801 806 10.1046/j.1365-2036.2000.00753.x 1:CAS:528:DC%2BD3cXltFSltb8%3D 10848665 (Pubitemid 30352748)
12. C Prantera F Zannoni ML Scribano E Berto A Andreoli A Kohn C Luzi 1996 An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin Am J Gastroenterol 91 328 332 1:CAS:528:DyaK28XhvVWnt7c%3D 8607501
13. AH Steinhart BG Feagan CJ Wong M Vandervoort S Mikolainis K Croitoru E Seidman DJ Leddin A Bitton E Drouin A Cohen GR Greenberg 2002 Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial Gastroenterology 123 33 40 10.1053/gast.2002.34225 1:CAS:528:DC%2BD38Xmt1aiurc%3D 12105831 (Pubitemid 34747523)
14. L Sutherland J Singleton J Sessions S Hanauer E Krawitt G Rankin R Summers H Mekhjian N Greenberger M Kelly, et al. 1991 Double blind, placebo-controlled trial of metronidazole in Crohn's disease Gut 32 1071 1075 10.1136/gut.32.9.1071 1:STN:280:DyaK38%2FgvFCktQ%3D%3D 1916494
15. B Ursing T Alm F Barany I Bergelin K Ganrot-Norlin J Hoevels B Huitfeldt G Jarnerot U Krause A Krook B Lindstrom O Nordle A Rosen 1982 A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result Gastroenterology 83 550 562 1:STN:280:DyaL383js1Oqsw%3D%3D 6124474 (Pubitemid 12096925)
16. C Buning H Lochs 2006 Conventional therapy for Crohn's disease World J Gastroenterol 12 4794 4806 16937460
17. Z-D Jiang S Ke E Palazzini L Riopel HL DuPont 2000 In vitro activity and fecal concentration of rifaximin after oral administration Antimicrob Agents Chemother 44 2205 2206 10.1128/AAC.44.8.2205-2206.2000 1:CAS:528: DC%2BD3cXltlShtrg%3D 10898704 (Pubitemid 30484455)
18. HL DuPont Z-D Jiang PC Okhuysen CD Ericsson FJ de la Cabada S Ke MW DuPont F Martinez-Sandoval 2005 A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea Ann Intern Med 142 805 812 1:CAS:528:DC%2BD2MXltFCnu70%3D 15897530
19. R Steffen DA Sack L Riopel ZD Jiang M Sturchler CD Ericsson B Lowe P Waiyaki M White HL DuPont 2003 Therapy of travelers' diarrhea with rifaximin on various continents Am J Gastroenterol 98 1073 1078 10.1111/j.1572-0241.2003. 07283.x 1:CAS:528:DC%2BD3sXksVentrc%3D 12809830 (Pubitemid 36733769)
20. ZD Jiang HL DuPont 2005 Rifaximin: in vitro and in vivo antibacterial activity-a review Chemotherapy 51 suppl 1 67 72 10.1159/000081991 1:CAS:528:DC%2BD2MXjsFyku7k%3D 15855749 (Pubitemid 40663191)
21. S Fiorucci E Distrutti A Mencarelli M Barbanti E Palazzini A Morelli 2002 Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis Digestion 66 246 256 10.1159/000068362 1:CAS:528:DC%2BD3sXitFaisL0%3D 12592101 (Pubitemid 36578775)
22. WR Best JM Becktel JW Singleton FJ Kern 1976 Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study Gastroenterology 70 439 444 1:STN:280:DyaE287hvVGmtg%3D%3D 1248701
23. I Shafran LK Johnson 2005 An open-label evaluation of rifaximin in the treatment of active Crohn's disease Curr Med Res Opin 21 1165 1169 10.1185/030079905X53252 1:CAS:528:DC%2BD2MXhtFGltrzL 16083525 (Pubitemid 41140719)
24. C Prantera H Lochs M Campieri ML Scribano GC Sturniolo F Castiglione M Cottone 2006 Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin Aliment Pharmacol Ther 23 1117 1125 10.1111/j.1365-2036.2006.02879.x 1:CAS:528:DC%2BD28Xlt1aktb8%3D 16611272 (Pubitemid 43779351)
25. P Gionchetti F Rizzello KM Lammers C Morselli L Sollazzi S Davies R Tambasco C Calabrese M Campieri 2006 Antibiotics and probiotics in treatment of inflammatory bowel disease World J Gastroenterol 12 3306 3313 1:CAS:528:DC%2BD28XnsFWkt78%3D 16733845 (Pubitemid 43933773)
26. FN Aberra CM Brensinger WB Bilker GR Lichtenstein JD Lewis 2005 Antibiotic use and the risk of flare of inflammatory bowel disease Clin Gastroenterol Hepatol 3 459 465 10.1016/S1542-3565(05)00020-0 15880315 (Pubitemid 40616911)
27. P Rutgeerts M Hiele K Geboes M Peeters F Penninckx R Aerts R Kerremans 1995 Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection Gastroenterology 108 1617 1621 10.1016/0016-5085(95)90121-3 1:STN:280:DyaK2M3osF2ktg%3D%3D 7768364
28. P Rutgeerts G Van Assche S Vermeire G D'Haens F Baert M Noman I Aerden G De Hertogh K Geboes M Hiele A D'Hoore F Penninckx 2005 Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial Gastroenterology 128 856 861 10.1053/j.gastro.2005.01.010 1:CAS:528:DC%2BD2MXjvV2qtrk%3D 15825069 (Pubitemid 40523538)
29. I Shafran P Burgunder 2008 Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series Am J Gastroenterol 103 2158 2160 10.1111/j.1572-0241.2008.01982-16.x 18796124